Delcath Investor Presentation (NASDAQ: DCTH)

Transcription

1 Delcath Investor Presentation (NASDAQ: DCTH) Agst DELCATH SYSTEMS, INC

2 Forward-looking Statements This presentation contains forward-looking statements, within the meaning of the federal secrities laws, related to ftre events and ftre financial performance which inclde statements abot or expectations, beliefs, plans, objectives, intentions, goals, strategies, assmptions and other statements that are not historical facts. Forward-looking statements are sbject to known and nknown risks and ncertainties and are based on potentially inaccrate assmptions, which cold case actal reslts to differ materially from expected reslts, performance or achievements expressed or implied by statements made herein. Or actal reslts cold differ materially from those anticipated in forward-looking statements for many reasons, inclding, bt not limited to, ncertainties relating to: the timing and reslts of ftre clinical trials inclding withot limitation the OM, HCC, ICC, and mcrc trials in the Company s Clinical Development Program, clinical adoption, se and reslting sales, if any, for the CHEMOSAT system in Erope, or ability to obtain reimbrsement for the CHEMOSAT system in varios markets, inclding withot limitation Germany and the United Kingdom and the impact on sales, if any, of reimbrsement in these markets inclding ZE reimbrsement in the German market, or ability to sccessflly commercialize the Melphalan/HDS system and the potential of the Melphalan/HDS system as a treatment for patients with primary and metastatic disease in the liver, the Company's ability to satisfy the remaining reqirements of the FDA's Complete Response Letter relating to the oclar melanoma indication and the timing of the same, approval of the Melphalan/HDS system by the U.S. FDA, the impact of presentations and abstracts at major medical meetings and congresses (SSO, ASCO, CIRSE, ESMO, EADO, RSNA) and ftre clinical reslts consistent with the data presented, approval of the crrent or ftre Melphalan/HDS system for delivery and filtration of melphalan or other chemotherapetic agents for varios indications in the U.S. and/or in foreign markets, actions by the FDA or other foreign reglatory agencies, or ability to sccessflly enter into strategic partnership and distribtion arrangements in foreign markets and the timing and revene, if any, of the same, ncertainties relating to the timing and reslts of research and development projects, and ncertainties regarding or ability to obtain financial and other resorces for any clinical trials, research, development, and commercialization activities. These factors, and others, are discssed from time to time in or filings with the Secrities and Exchange Commission inclding the section entitled Risk Factors in or most recent Annal Report on Form 10-K and or Reports on Form 10-Q and Form 8-K. 2 DELCATH SYSTEMS, INC

3 Delcath Systems Making a clinically meaningfl difference for patients with cancers of the liver Focsed on treatment of primary/metastatic liver cancers Proprietary system delivers high-dose chemotherapy (melphalan) directly to the liver with extra-corporeal filtration to limit systemic toxicity Commercial Stage in the EU Late-stage clinical development in the US Prsing orphan indications in metastatic oclar melanoma (OM), hepatocelllar carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) Concentrating the Power of Chemotherapy for Disease Control in the Liver 3 DELCATH SYSTEMS, INC

4 Cancers of the Liver - A Major Unmet Medical Need Large global patient poplation of ~1.2 million* patients diagnosed annally with primary or metastatic liver cancer Liver a common site of metastases and often the life-limiting organ for cancer patients Prognosis is poor, OS generally <12 months Crrently available/emerging therapies limited * SOURCE 2008 GLOBOCAN 4 DELCATH SYSTEMS, INC

5 Limitations of Crrent Liver Cancer Treatments Systemic Toxicities Limited efficacy in liver Systemic Chemotherapy Temozolomide, carboplatin/ Paclitaxel Regional Therapy Isolated Hepatic Perfsion Srgical Resection Focal Interventions Y-90, Chemo/ Radiofreqency Ablation Invasive Emerging Therapy Checkpoint Inhibitors, Immnotherapy Not Repeatable Small % of PTS are candidates Limited Efficacy in Diffse Disease 5 DELCATH SYSTEMS, INC

6 Or Soltion Liver Focsed Disease Control CHEMOSAT Melphalan/HDS prodct niqely positioned to treat the entire liver as a standalone or as complementary therapy System isolates the liver circlation, delivers a high concentration of chemotherapy (melphalan), filters most chemotherapy ot of the blood prior to retrning it to the patient Repeatable procedre typically takes ~2-3 hors Liver Isolated Via Doble Balloon Catheter In IVC Melphalan Infsed Directly Into Liver Via Catheter In Hepatic Artery Blood Exiting The Liver Filtered By Proprietary Extra-corporeal Filters 6 DELCATH SYSTEMS, INC

7 Benefits Demonstrated in Prior Phase 3 Trial Reslts of a Randomized Controlled Mlticenter Phase 3 Trial of PHP vs. Best Available Care for Patients with Melanoma Liver Metastases Annals of Oncology 2015 Hepatic Progression Free Srvival (IRC Assessment) Overall Progression Free Srvival (INV Assessment) Proportion of patients srviving 5.2 mo Perctaneos Hepatic Perfsion (PHP) Best alternative care (BAC) mo Proportion of patients srviving Perctaneos Hepatic Perfsion (PHP) Best alternative care (BAC) Months n=93 (44 PHP, 49 BAC) Intent to Treat Analysis hpfs PFS Improvement 5.3 mos 3.8 mos Hazard Ratio Confidence 95%, %, P Vale = < Months 4 PTS alive as of Dec 2015 (OS range 6-9 years) All were recipients of melphalan 7 DELCATH SYSTEMS, INC

8 Initial Commercialization CHEMOSAT Available At Major Cancer Centers Throghot Eropean Region CE Marked as Class IIb Medical Device with broad indication >300 commercial procedres performed Broad range of tmor types treated Expansion into Trkey March 2016 National reimbrsement established in Germany for 2016 after <3 years of commercial activity Prospective Registry activated in DELCATH SYSTEMS, INC

9 Growing & Expanding Clinical Utilization EU clinical adoption increasing Physicians opting to retreat patients as familiarity/confidence grows Usage expanding beyond initial se in metastatic OM Usage incldes patients with CM, HCC, ICC, CRC, breast mets, NET mets, pancreatic, mcosal melanoma, sarcoma, and gastric mets Data from EU experience presented at mltiple medical conferences in DELCATH SYSTEMS, INC

10 2015 Data Presentations Abstract N= Efficacy Toxicity/AEs Notes OS CR PR SD HPFS Zager SSO 30 (CM, OM) 736 days Sothampton - ASCO LUMC - CIRSE days Stdy analyzed filtration efficiency & TX tolerability Sothampton - CIRSE Leiden, Erasms ECCO/ESMO 9 8 PTS still alive, 7 w/o disease progression Sothampton -EADO days (@ ct off) GR1 (n=12), GR2 (n=13), GR3(n=5) GR4(n=1) GR3(n=7) Decrease red/white BC cont; 3 PTS rec d blood TF Non-hemo AE s n=3 GR2(89%), GR3 (n=4), GR2-4 netropenia (n=4) OS reslts provide confidence for new P3 Trial 11 pts alive median 280 days, 1 CR ongoing >1yr Filtration efficiency =93% 11 pts alive median 280 days; 1 CR >1yr post TX TX overall well tolerated TX can be sed safely by exp team; high PFS and OS in select OM pts Leiden - EADO 10 DELCATH SYSTEMS, INC 20 (CRC, OM) 10 PTS remain in FU, 4 w/o progression; Max FU= Frankfrt - EADO GR 3,4 n=4 7 lekopenia, 6 thrombocytopenia, 2 netropenia CM=ctaneos Melanoma, OM=Oclar Melanoma, CRC=Colorectal Cancer TX appears safe/effective in select OM PTS 11 of 14 PTS evalable; TX potential demonstrated

11 2015 Data Presentations Abstract N= Efficacy Toxicity/AEs Notes OS CR PR SD HPFS Zager SSO 30 (CM, OM) 736 days Sothampton - ASCO LUMC - CIRSE days Stdy analyzed filtration efficiency & TX tolerability Sothampton - CIRSE Leiden, Erasms ECCO/ESMO 9 8 PTS still alive, 7 w/o disease progression Sothampton -EADO days (@ ct off) GR1 (n=12), GR2 (n=13), GR3(n=5) GR4(n=1) GR3(n=7) Decrease red/white BC cont; 3 PTS rec d blood TF Non-hemo AE s n=3 GR2(89%), GR3 (n=4), GR2-4 netropenia (n=4) OS reslts provide confidence for new P3 Trial 11 pts alive median 280 days, 1 CR ongoing >1yr Filtration efficiency =93% 11 pts alive median 280 days; 1 CR >1yr post TX TX overall well tolerated TX can be sed safely by exp team; high PFS and OS in select OM pts Leiden - EADO 11 DELCATH SYSTEMS, INC 20 (CRC, OM) 10 PTS remain in FU, 4 w/o progression; Max FU= Frankfrt - EADO GR 3,4 n=4 7 lekopenia, 6 thrombocytopenia, 2 netropenia CM=ctaneos Melanoma, OM=Oclar Melanoma, CRC=Colorectal Cancer TX appears safe/effective in select OM PTS 11 of 14 PTS evalable; TX potential demonstrated

12 2015 Data Presentations Abstract N= Efficacy Toxicity/AEs Notes OS CR PR SD HPFS Zager SSO 30 (CM, OM) 736 days Sothampton - ASCO LUMC - CIRSE days Stdy analyzed filtration efficiency & TX tolerability Sothampton - CIRSE Leiden, Erasms ECCO/ESMO 9 8 PTS still alive, 7 w/o disease progression Sothampton -EADO days (@ ct off) GR1 (n=12), GR2 (n=13), GR3(n=5) GR4(n=1) GR3(n=7) Decrease red/white BC cont; 3 PTS rec d blood TF Non-hemo AE s n=3 GR2(89%), GR3 (n=4), GR2-4 netropenia (n=4) OS reslts provide confidence for new P3 Trial 11 pts alive median 280 days, 1 CR ongoing >1yr Filtration efficiency =93% 11 pts alive median 280 days; 1 CR >1yr post TX TX overall well tolerated TX can be sed safely by exp team; high PFS and OS in select OM pts Leiden - EADO 12 DELCATH SYSTEMS, INC 20 (CRC, OM) 10 PTS remain in FU, 4 w/o progression; Max FU= Frankfrt - EADO GR 3,4 n=4 7 lekopenia, 6 thrombocytopenia, 2 netropenia CM=ctaneos Melanoma, OM=Oclar Melanoma, CRC=Colorectal Cancer TX appears safe/effective in select OM PTS 11 of 14 PTS evalable; TX potential demonstrated

13 2015 Data Presentations Abstract N= Efficacy Toxicity/AEs Notes OS CR PR SD HPFS Zager SSO 30 (CM, OM) 736 days Sothampton - ASCO LUMC - CIRSE days Stdy analyzed filtration efficiency & TX tolerability Sothampton - CIRSE Leiden, Erasms ECCO/ESMO 9 8 PTS still alive, 7 w/o disease progression Sothampton -EADO days (@ ct off) GR1 (n=12), GR2 (n=13), GR3(n=5) GR4(n=1) GR3(n=7) Decrease red/white BC cont; 3 PTS rec d blood TF Non-hemo AE s n=3 GR2(89%), GR3 (n=4), GR2-4 netropenia (n=4) OS reslts provide confidence for new P3 Trial 11 pts alive median 280 days, 1 CR ongoing >1yr Filtration efficiency =93% 11 pts alive median 280 days; 1 CR >1yr post TX TX overall well tolerated TX can be sed safely by exp team; high PFS and OS in select OM pts Leiden - EADO 13 DELCATH SYSTEMS, INC 20 (CRC, OM) 10 PTS remain in FU, 4 w/o progression; Max FU= Frankfrt - EADO GR 3,4 n=4 7 lekopenia, 6 thrombocytopenia, 2 netropenia CM=ctaneos Melanoma, OM=Oclar Melanoma, CRC=Colorectal Cancer TX appears safe/effective in select OM PTS 11 of 14 PTS evalable; TX potential demonstrated

14 Peer Reviewed Pblications Perctaneos Isolated Hepatic Perfsion for the Treatment of Unresectable Liver Malignancies, Cardiovasclar and Interventional Radiology December 2015 Crrent Stats of Perctaneos Hepatic Perfsion as Regional Treatment for Patients with Unresectable Metastases: A Review, American Oncology and Hematology Review 2014 Unresectable Isolated Hepatic Metastases From Solid Psedopapillary Neoplasm of the Pancreas: A Case Report of Chemosatration with High Dose Melphalan, Pancreatology September 2014 Chemosatration with Perctaneos Hepatic Perfsion for Unresectable Metastatic Melanoma or Sarcoma to the Liver: A Single Instittion Experience, Jornal of Srgical Oncology October 2013 and Isolated Hepatic Perfsion for Metastatic Melanoma, Jornal of Srgical Oncology September DELCATH SYSTEMS, INC Metastatic Melanoma to the Liver: A Contemporary And Comprehensive Review of Srgical, Systemic, And Regional Therapetic Options, Cancer December 2013

15 6 th Eropean Post-Chicago 2016 Chemosatration Via Perctaneos Hepatic Perfsion An Update on A Single Centre Experience of Treating Metastatic Uveal Melanoma Sothampton University (United Kingdom) Methods A retrospective evalation of 27 patients treated with CHEMOSAT over 4 years; analysis of srvival, tmor response, time to progression and treatment related adverse events; 25 patients received 43 treatments, 24 were evalable Reslts - 14 patients remained alive after median 290 days o 1 complete response (4%), 5 partial responses (21%), 12(50%) stable disease >90 days o Progression free srvival for patients who had progressed was 181 days at the time of data ct off o 11/17 patients alive >1 year following their first treatment with projected OS of 511 o 11 deaths from disease progression occrred median 264 days following first treatment; no treatment related deaths Adverse Events (AEs) - treatment overall was well tolerated o Non-hematological AEs were rare (6) o Most common adverse events was transient, mild grade 2 transaminitis (64%) and thrombocytopenia (88%); grade 3 anemia seen in 36% of patients, grade 2-4 netropenia was seen in 24% patients Conclsion PHP achieves nprecedented progression free and overall srvival, and can be sed safely by an experienced mltidisciplinary team to administer liver directed therapy in select UM patients. 15 DELCATH SYSTEMS, INC

16 Mlti-Billion Dollar Opportnity in Orphan Indications EU & US TAM Fastest Path to US Market Approval Cancer Type Annal Incidence 1 Eligible PTS 2 Market Opportnity Annal Potential (Millions) 3,4 Oclar Melanoma 5,700-8,600 2,600-4,300 ~$104-$430 Intrahepatic Cholangiocarcinoma (ICC) Hepatocelllar Carcinoma (HCC) 11,500 6,500 ~$260-$660 64,500 7,600-14,700 ~$304-$1,470 Colorectal (CRC) 411,000 40,000-55,000 ~$1,600-$5,500 Total EU & U.S. 492, ,600 56,700-80,500 ~$2,268--$8,060 Notes: 1) Globocan, American Cancer Society 2) LEK, Strategy&, Company Estimates 3) Assmes 2-4TX/patient 4) Assmes ~$20,000-$25,000 USD/TX 16 DELCATH SYSTEMS, INC

17 Clinical Development Program Tmor Type Program IIT P2 P3 Upcoming Milestones Oclar Melanoma (OM) FOCUS Trial P3 Pivotal Stdy in Hepatic Dominant OM ü 1 st PT Enrolled Expansion of US/EU Trial Sites Hepatocelllar Carcinoma (HCC) Intrahepatic Cholangiocarcinoma (ICC) 202 HCC/ICC Trial (EU Only) 201 HCC Trial (US Only) Interim Efficacy/Safety Data Other Select Investigator Trials in HCC/CRC Presentation of INV Data Mlti-Histology Prospective Commercial Registry (EU Only) N/A Data on 1 st 20 PTS IIT=Investigator Initiated Trials P2= Phase 2 P3= Phase 3 17 DELCATH SYSTEMS, INC

18 Global Phase III Clinical Trial Clinical Trial For Patients with Hepatic-Dominant Oclar Melanoma Mltinational, Mlticenter Randomized Phase 3 Trial in Patients with Hepatic Dominant Oclar Melanoma (N=240) R 1:1 Melphalan/HDS TX every 6-8 weeks 6 cycles BAC Dacarbazine,TACE, ipilimmab, or pembrolizmab determined by instittion SOC Primary Endpoint (Overall Srvival) Secondary Endpoints (Progression Free Srvival, Objective Response Rate) Safety, Pharmacokinetics, QoL (Rigoros Analyses to Assess Risk/Benefit Profile) 18 DELCATH SYSTEMS, INC

19 Recent Financing $35.0 million senior secred convertible notes issed Jne 2016 sbject to certain eqity conditions $32.2 million aggregate proceeds to fnd clinical development programs, commercial activities & ongoing operations $3.0 million nrestricted tranche immediately and freely available $29.2 million restricted cash 85% warrant coverage 19 DELCATH SYSTEMS, INC

20 Cash & Capital Resorces Cash & Cash Eqivalents $7.5 million at Jne 30, 2016 Debt $35.0 million at Jne 30, 2016 Restricted Cash $30.3 million at Jne 30, 2016 Shares Otstanding 1.5 million (9.0 million flly dilted 1 ) at Jne 30, ) Flly dilted incldes approximately 42,000 options, 19,000 nvested restricted shares and 7.4 million warrants Focsed Spending and Resorces to Spport Exection of Near-term Plan 20 DELCATH SYSTEMS, INC

21 Vale Drivers Near Term Milestones 1H 2016 FDA SPA Approved FOCUS Phase 3 Trial Initiated Interim Phase 2 Program Data EU Registry Data Readot #1 2H 2016 German ZE Reimbrsement Level Defined P2 ICC Cohort Enrollment Completed EU Registry Data Readot #2 Contined Data Presentation & Pblication Execting on Mltiple Fronts to Create Vale 21 DELCATH SYSTEMS, INC

22 Investment Highlights Attractive mlti-billion dollar orphan drg bsiness model Uniqe, highly differentiated soltion Late-stage asset in US with active clinical development program Early commercial activity in EU with increasing sales/procedre volmes Imminent valation drivers ü ü FDA SPA Agreement P3 Trial Initiation ² 2016 German Reimbrsement 22 DELCATH SYSTEMS, INC

23 23 DELCATH SYSTEMS, INC 2016 DELCATH SYSTEMS, INC. ALL RIGHTS RESERVED Delcath and CHEMOSAT are registered trademarks of Delcath Systems, Inc.

24 Appendix 24 DELCATH SYSTEMS, INC

25 SSO 2015 Hepatic Progression Free and Overall Srvival after Regional Therapy to the Liver for Metastatic Melanoma - Moffitt Cancer Center (Tampa, FL) Methods o Retrospective analysis of 30 patients with oclar or ctaneos melanoma treated with Melphalan/HDS (n=10), chemoembolization (CE, n=12), and yttrim-90 (Y90, n=6) Reslts - o Stdy showed significant difference in hepatic progression free srvival (HPFS) for Melphalan/HDS (310 days), CE (80 days), Y90 (54 days) o Median overall srvival (OS) longest for Melphalan/HDS (736 days) vs Y90 (285 days) CE (265 days), bt did not reach statistical significance Conclsion - Athors conclded that HPFS and progression free srvival (PFS) were significantly prolonged with Melphalan/HDS vs CE and Y90 25 DELCATH SYSTEMS, INC

26 ASCO 2015 Single Centre Experience of Chemosatration Perctaneos Hepatic Perfsion in the Treatment of Metastatic Uveal Melanoma - Sothampton University Hospital (UK) Methods - Analysis of 20 oclar melanoma patients who received 34 TX Reslts - o Eleven patients remain alive after a median of 280 days with one complete response ongoing at >1 year o From the diagnosis of liver metastases, 11 patients (55%) srvived to one year and 3 (15%) for >2 years; no procedre related deaths were seen o ORR 85%: 2 patients (10%) demonstrated stable disease for >3 months, 13 patients (65%) had a partial response, 2 patients (10%) demonstrated complete response o Nine deaths from disease progression occrred after a median of 264 days from the first procedre Adverse Events - o Early AEs often expected with perctaneos hepatic perfsion (PHP) were observed inclding coaglopathy, electrolyte distrbances and transient transaminases (elevated liver enzymes). Rare late AEs (1 patient each) inclded hair loss, skin rash, myelosppression and persistent transaminases (elevated liver enzymes) o AEs seen were grade 1 (n=12), 2 (n=13), 3 (n=5) and 4 (n=1) o Grade 4 complication was plmonary edema de to flid overload Conclsion - reslts show that PHP (CHEMOSAT) can be sed safely to control hepatic metastases in selected UM patients with a high rate of hepatic progression free and excellent overall srvival 26 DELCATH SYSTEMS, INC

27 CIRSE 2015 Safety and efficacy of Delcath 2 nd Generation filter in PHP with melphalan for nresectable hepatic metastases of colorectal cancer and veal melanoma - Leiden University Medical Center (the Netherlands) 15 PHP procedres performed with CHEMOSAT on 10 pts; PK blood baseline, set intervals PHP performed with melphalan dose of 3mg/kg; 1st blood sample filtration efficiency = 93% Grade 3 complications (mostly lekocytopenia, thrombocytopenia) in 7 pts; febrile netropenia (w/bacterial pharyngitis) in 1 pts (not seen following introdction of growth factors) Conclsion - 2 nd Generation filter efficiency very high; PHP associated with no mortality and acceptable morbidity Lessons and Early Reslts from the Largest Single Center Experience in Erope of Treating Oclar Melanoma Liver Metastases with Chemosatration via Perctaneos Hepatic Perfsion - Sothampton University (United Kingdom) Retrospective analysis of 22 pts; 20 received TX w/php 11 pts alive after median 280 days; one complete response > 1yr post TX 9 deaths from disease progress after median 264 days post TX Complete response in liver in 2 pts (10%), 13 pts (65%) had partial liver response, 2 pts (10%) had stable disease > 3mos Conclsion - PHP effective palliative TX in bleak disease with an acceptable side-effect profile 27 DELCATH SYSTEMS, INC

28 ECCO 2015 Treating Unresectable Liver Metastases of Uveal Melanoma with (Perctaneos) Isolated Hepatic Perfsion with Melphalan: Reslts from Two Experienced Centers - Leiden University Medical Center, Erasms Medical Center (the Netherlands) Methods - Investigators compared TX with IHP and PHP for oclar melanoma liver metastases Reslts - o IHP cohort (n=30) treated between 1999 and 2009 PFS was 6 mos Disease recrrence mainly in the liver OS was 10 mos (vs 6 mos historic avg for IHP) o PHP cohort (n=9); PTS received 15 PHP TX since Feb 2014 Max follow p period was 14 mos 8 PTS still alive, 7 withot disease progression Decrease in red/white blood cell cont observed following TX; 3 PTS received blood transfsion TX overall was well tolerated Conclsion - PHP appears to be effective/safe procedre in select patients with nresectable liver metastases from CRC or OM and can be repeated 28 DELCATH SYSTEMS, INC

29 EADO 2015 Treating Unresectable Liver Metastases Of Uveal Melanoma With Perctaneos Hepatic Perfsion With Melphalan, Leiden University Medical Center, Erasms Cancer Institte (the Netherlands) presented by Dr. Mark Brgmans (Leiden) Methods - two-center Phase 2 stdy aims to evalate 20 patients with veal, or oclar melanoma treated with perctaneos hepatic perfsion (PHP) performed with CHEMOSAT; data from the first 11 patients with a maximm follow p period of 16 months were presented o Primary endpoints are response rate (RECIST criteria) following two treatments at 6 week interviews, percentage of patients with stable disease o Secondary endpoints are safety, overall srvival, hepatic progression free srvival, qality of life Reslts -18 treatments performed on 11 patients, maximm follow p crrently 16 months o 10 patients remain in follow p, 4 withot progression of disease Adverse Events - grade 3 or 4 toxicity observed in 4 patients, managed with blood transfsion or platelet infsion Conclsion - CHEMOSAT appears to be effective and safe procedre in select patients with nresectable liver metastases of veal melanoma and can be repeated 29 DELCATH SYSTEMS, INC

30 EADO 2015 Chemosatration with Perctaneos Hepatic Perfsion of Melphalan for Hepatic Metastases from Uveal Melanoma: Mlti-instittional Evalation, poster presented by lead athor Prof. Thomas Vogl, Frankfrt University Hospital Methods - retrospective evalation of non-resectable hepatic metastases from veal melanoma treated with CHEMOSAT o 14 patients treated ; patients received 1-3 treatments o 11 PTS evalated by RECIST criteria; srvival time analysis performed, complications registered Reslts - 4 (36%) partial response, 5 (46%) stable disease, 2 (18%) progressive disease o Srvival time ranged from 1. 5 months to 23 months (median OS 6.5 months) o Time to progression for two patients who progressed was 6.2 months in one patient; the other died 1.6 months after evalation Adverse Events treatment well tolerated by all 14 patients o 7 lekopenia, 6 thrombocytopenia, 2 netropenia Conclsion - CHEMOSAT has been manifested as a potential treatment for patient with nonresectable hepatic metastases of veal melanoma 30 DELCATH SYSTEMS, INC